Nurse Practitioner in Yellville, AR Accepting Medicare
6 Nurse Practitioner nurses found. Showing 1 - 6
 Mrs. Michel T Villiger, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 414 W Old Main St, Yellville, AR 72687 Phone: 870-449-4221 Fax: 870-449-6777 |
Nancy S Svehla, APN Nurse Practitioner - Family Medicare: Accepting Medicare Assignments Practice Location: 358 East Valley Street, Yellville, AR 72687 Phone: 870-449-7000 Fax: 870-449-7010 |
Shanna L Pearson, ANP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 707 Highway 202 W, Yellville, AR 72687 Phone: 870-449-4259 Fax: 870-449-6364 |
 John Green Iii, Nurse Practitioner - Family Medicare: Medicare Enrolled Practice Location: 358 East Valley Street, Yellville, AR 72687 Phone: 870-449-7000 |
Derainey R. Smith, FNP Nurse Practitioner - Family Medicare: Accepting Medicare Assignments Practice Location: 437 Highway 62 East, Yellville, AR 72687 Phone: 870-449-9355 Fax: 870-423-7178 |
Mrs. Shelia Mae Howerton, APRN Nurse Practitioner - Acute Care Medicare: Accepting Medicare Assignments Practice Location: 358 East Valley Street, Yellville, AR 72687 Phone: 870-449-7000 Fax: 866-554-1757 |
News Archive
Brentuximab vedotin-chemotherapy combination clinical trial for Hodgkin lymphoma announced
Seattle Genetics, Inc. and Millennium Pharmaceuticals, Inc.: The Takeda Oncology Company today announced that they have initiated a phase I clinical trial of brentuximab vedotin (SGN-35) in combination with chemotherapy for the treatment of newly diagnosed Hodgkin lymphoma patients. Brentuximab vedotin is an antibody-drug conjugate (ADC) that is also in single-agent clinical trials, including a pivotal trial for relapsed and refractory Hodgkin lymphoma and a phase II trial for systemic anaplastic large cell lymphoma.
Child care may affect entire community's risks of infection
Any parent knows how quickly a cold or a cough can spread between children who play together. However, child care may also affect an entire community's carriage of potentially dangerous bacteria known as Streptococcus pneumoniae, according to an article in the April 1 issue of Clinical Infectious Diseases, now available online.
OrthoDynamix' ArthroSteer 3.5mm Ablator for general surgical use receives FDA clearance
OrthoDynamix announced today that it has received FDA clearance for its new device, ArthroSteer 3.5mm Ablator, a mono polar electrosurgical device, for general surgical use, including the orthopedic and arthroscopic applications for resection, ablation, excision of soft tissue, hemostasis of blood vessels, and coagulating soft tissue in, but not limited to the knee, shoulder, and primarily the hip.
Phase I/II clinical trial of novel dialysate completed by Zytoprotec
Zytoprotec, a company developing drugs based on active cytoprotection, today announced the completion of a Phase I/II clinical trial with its lead product, PD-protec™. The product is developed to improve the treatment of patients with kidney failure.
Chemotherapy best second-line option for EGFR wild-type NSCLC
Chemotherapy is more effective than erlotinib as second-line therapy in people with advanced non-small-cell lung cancer and wild-type epidermal growth factor receptor genotype, a randomized controlled trial has found.
› Verified 4 days ago